Latest & greatest articles for clonazepam

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clonazepam or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clonazepam and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clonazepam

1. Clonazepam add-on therapy for drug-resistant epilepsy. (Abstract)

Clonazepam add-on therapy for drug-resistant epilepsy. This is an updated version of the original Cochrane Review published in 2018, Issue 5. Epilepsy affects over 70 million people worldwide, and nearly a quarter of patients with seizures have drug-resistant epilepsy. People with drug-resistant epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life.To assess the efficacy and tolerability of clonazepam when used as an add-on therapy (...) , controlled trials from Embase, ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (ICTRP).Double-blind randomised controlled studies of add-on clonazepam in people with resistant focal or generalised onset seizures, with a minimum treatment period of eight weeks. The studies could be of parallel or cross-over design.Two review authors independently selected studies for inclusion, extracted relevant data, and assessed trial quality. We contacted study

2020 Cochrane

2. Clonazepam monotherapy for treating people with newly diagnosed epilepsy. (Abstract)

Clonazepam monotherapy for treating people with newly diagnosed epilepsy. Epilepsy is one of the most common neurological disorders worldwide, with an age-adjusted prevalence of 4 to 8 per 1000 population and an age-adjusted incidence of 44 per 100,000 person-years in developed countries. Monotherapy represents the best therapeutic option in people with newly diagnosed epilepsy.To assess the efficacy and tolerability of oral clonazepam used as monotherapy for newly diagnosed epilepsy, when (...) compared with placebo or a different anti-seizure medication.The following databases were searched on 24 July 2018: the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid) 1946 to 24 July 2018, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP).We included randomized controlled trials (RCTs) or quasi-RCTs comparing oral clonazepam used

2020 The Cochrane database of systematic reviews

3. Ziprasidone, haloperidol and clonazepam intramuscular administration in the treatment of agitation symptoms in Chinese patients with schizophrenia: A network meta-analysis. (Full text)

Ziprasidone, haloperidol and clonazepam intramuscular administration in the treatment of agitation symptoms in Chinese patients with schizophrenia: A network meta-analysis. Agitation is very common in patients with acute stage schizophrenia, and injection of antipsychotics and clonazepam is widely used. Network meta-analysis of these comparisons among three injection treatments has been seldom reported.To compare the efficacy and safety of various injections for agitation symptoms in Chinese (...) and Evaluation (GRADE) was used to assess the strength of evidence.A total of 15 studies were included in the network meta-analysis. There were 11 studies comparing ziprasidone with haloperidol, and four studies comparing haloperidol with clonazepam. The results showed that ziprasidone is more effective than haloperidol and clonazepam (sucra: 77.2, 72.8 and 0) in the treatment of agitation symptoms. There was the effect size (standardised mean difference (SMD)) in the three groups: haloperidol: SMD=2.278, 95

2020 General psychiatry PubMed abstract

4. Clonazepam

Clonazepam Top results for clonazepam - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for clonazepam The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

5. Clonazepam add-on therapy for refractory epilepsy in adults and children. (Full text)

Clonazepam add-on therapy for refractory epilepsy in adults and children. Epilepsy affects about 50 million people worldwide, nearly a quarter of whom have drug-refractory epilepsy. People with drug-refractory epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life.To assess the efficacy and tolerability of clonazepam when used as an add-on therapy for adults and children with refractory focal onset or generalised onset epileptic (...) seizures, when compared with placebo or another antiepileptic agent.We searched the following databases on 14 September 2017: Cochrane Epilepsy Group Specialized Register, Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 14 September 2017), ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP).Double-blind randomised controlled studies of add-on clonazepam in people with refractory focal

2018 Cochrane PubMed abstract

6. Low-level Laser Therapy (LLLT) Is Superior to Clonazepam at Reducing the Perception of Pain in Adults Suffering From Burning Mouth Syndrome

Low-level Laser Therapy (LLLT) Is Superior to Clonazepam at Reducing the Perception of Pain in Adults Suffering From Burning Mouth Syndrome UTCAT3234, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Low-level Laser Therapy (LLLT) Is Superior to Clonazepam at Reducing the Perception of Pain in Adults Suffering From Burning Mouth Syndrome Clinical Question In adults who suffer from burning mouth syndrome (BMS), can low (...) -level laser therapy (LLLT) reduce pain perception better than the traditional clonazepam treatment? Clinical Bottom Line Based on this preliminary trial, LLLT is more effective at reducing pain associated with burning mouth syndrome than the traditional treatment of clonazepam. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Arduino/2016 33 adults, 76% of whom were female, with burning mouth syndrome

2017 UTHSCSA Dental School CAT Library

7. Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis. (Abstract)

Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis. Clonazepam has been used in the treatment of burning mouth syndrome (BMS) for several decades. We conducted a meta-analysis to investigate the efficacy of clonazepam in the treatment of BMS.We conducted a search of the PubMed, MEDLINE, EMBASE, Web of Science (TS), and the Cochrane Library databases for relevant studies that met our eligibility criteria (up to September 22, 2015). Statistical (...) analyses were conducted using RevMan 5.2 and STATA 11.0 software.Three randomized controlled trials (RCTs) and two high-quality case-control studies involving 195 BMS patients were selected for this study. Our results show that clonazepam can reduce the oral pain sensation in patients with BMS (WMD: -3.72, 95% CI: -4.57, -2.86; P < 0.05; for all five studies). A positive therapeutic effect was demonstrated for both short-term (≤10 weeks) application (WMD: -1.44, 95% CI: -2.06, -0.82; P < 0.05) and long

2015 Oral diseases

8. Clonazepam for neuropathic pain and fibromyalgia in adults. (Full text)

Clonazepam for neuropathic pain and fibromyalgia in adults. Antiepileptic drugs have been used in pain management since the 1960s; some have shown efficacy in treating different neuropathic pain conditions. Clonazepam, a benzodiazepine, is an established antiepileptic drug, but its place in the treatment of neuropathic pain is unclear.To assess the analgesic efficacy and adverse effects of the antiepileptic drug clonazepam in neuropathic pain and fibromyalgia.We searched the Cochrane Central (...) Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 2). MEDLINE, and EMBASE to 28 February 2012, together with reference lists of retrieved papers and reviews, and ClinicalTrials.gov.We planned to include randomised, double-blind studies of eight weeks duration or longer, comparing clonazepam with placebo or another active treatment in chronic neuropathic pain or fibromyalgia.Two review authors would independently extract data for efficacy and adverse events, and examine issues

2012 Cochrane PubMed abstract

9. Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. (Abstract)

Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. Clonazepam and lorazepam are used in the treatment of acute mania but trial results are conflicting.Studies were identified by searching MEDLINE and EMBASE for lorazepam or clonazepam in acute mania between 1966 and 2000. Seven randomized controlled trials were found comparing clonazepam or lorazepam to placebo, haloperidol or lithium in acute mania. Data on 206 patients were analyzed.The heterogeneity of trial designs (...) and the use of different comparators necessitated a Bayesian hierarchical meta-analysis with three models: (a) random trial effect and fixed treatment effects, (b) random trial and treatment effects, (c) random trial and treatment effects with trial variance unknown. With all models, clonazepam decreased psychopathology scores statistically significantly with the following standardized responses: model (a): 1.26 (95% predictive interval (PI) 0.33 to 2.28), model (b): 1.21 (95% PI 0.08 to 2.53), model (c

2004 Journal of Affective Disorders